Key result
Oral alpha-tocopherol supplementation (1600 i.u. daily) for 8 weeks did not improve vasodilation to nitroprusside, acetylcholine, or bradykinin in patients with Type 2 diabetes (all P>0.1).
Why the study?
Does oral alpha-tocopherol improve endothelial function in subjects with uncomplicated Type 2 diabetes mellitus?
RCT (n=69)
Double-blind
Does oral alpha-tocopherol improve endothelial function in subjects with uncomplicated Type 2 diabetes mellitus?
p-value: p=>0.1
Oral alpha-tocopherol supplementation for 8 weeks does not improve endothelial dysfunction in patients with uncomplicated Type 2 diabetes mellitus.
Does not support alpha-tocopherol for endothelial dysfunction in type 2 diabetes; challenges prior hypotheses and leaves open other antioxidant strategies.
AIMS: Vascular endothelial dysfunction, an early marker of atherosclerosis, has been demonstrated in Type 2 diabetes mellitus (DM). Vitamin E preserves endothelial function in animal models of diabetes and reduces cardiovascular risk. We examined endothelial function and the effect of vitamin E supplements in uncomplicated Type 2 DM. METHODS: Forty-eight subjects with Type 2 DM and 21 controls had endothelial function assessed using forearm venous occlusion plethysmography with endothelium-independent (sodium nitroprusside) and dependent (acetylcholine, bradykinin) vasodilators. Those with diabetes received 1600 i.u. daily oral alpha-tocopherol or placebo, double-blind for 8 weeks, and had endothelial function reassessed. RESULTS: The diabetic group had higher HbA1c (6.9+/-1.4 vs 4.8+/-0.6%; P<0.01) and systolic (145+/-15 vs. 130+/-16 mm Hg; P<0.01) but not diastolic blood pressure (79+/-8 vs. 76+/-9 mm Hg; P = 0.15). There was blunted vasodilation to acetylcholine (15 microg/min; P<0.01) in subjects with diabetes. Vasodilation to sodium nitroprusside and bradykinin was similar (all P>0.1). Alpha-tocopherol did not affect vasodilation to nitroprusside (P>0.1), acetylcholine (P>0.1) or bradykinin (P>0.1). CONCLUSIONS: There may be receptor-specific endothelial dysfunction in subjects with uncomplicated Type 2 DM. This is not improved by treatment with alpha-tocopherol.
No takes yet. Share an insight, caveat, or question.
Gazis et al. (1999) conducted an RCT in Type 2 diabetes mellitus (n=69). Oral alpha-tocopherol vs. Placebo was evaluated on Vasodilation to sodium nitroprusside, acetylcholine, and bradykinin (p=>0.1). Oral alpha-tocopherol supplementation (1600 i.u. daily) for 8 weeks did not improve vasodilation to nitroprusside, acetylcholine, or bradykinin in patients with Type 2 diabetes (all P>0.1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: